Triple negative breast cancer: adjuvant chemotherapy effect on survival
The purpose of this study was to evaluate the overall survival of patients with triple negative breast cancer and the impact of different adjuvant chemotherapy regimens on survival. The study group consisted of 99 breast cancer patients with immunohistochemically confirmed triple negative breast can...
Gespeichert in:
| Veröffentlicht in: | Advances in medical sciences 2011-12, Vol.56 (2), p.285-290 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 290 |
|---|---|
| container_issue | 2 |
| container_start_page | 285 |
| container_title | Advances in medical sciences |
| container_volume | 56 |
| creator | Steponaviciene, L Lachej-Mikeroviene, N Smailyte, G Aleknavicius, E Meskauskas, R Didziapetriene, J |
| description | The purpose of this study was to evaluate the overall survival of patients with triple negative breast cancer and the impact of different adjuvant chemotherapy regimens on survival.
The study group consisted of 99 breast cancer patients with immunohistochemically confirmed triple negative breast cancer. The impact of various factors as well as the impact of different chemotherapy regimens on survival was evaluated.
The overall survival of breast cancer patients was 97.0% (95% CI 90.9–99.0), 84.9% (95% CI 76.1–90.6) and 66.5% (95% CI 55.5–75.3) 10, 30 and 60 months after diagnosis, respectively. Univariate analysis demonstrated that the following were significant risk factors for breast cancer patients survival: patient's age, stage of disease, tumour size, lymph node status, type of surgery and chemotherapy. Better survival was related to younger patients’ age, smaller tumour size, lower stage of disease, no lymph nodes involvement. Survival rates were higher among patients who received adjuvant chemotherapy and underwent quadrantectomy. In the multivariate statistical analysis the significant independent prognostic variables influencing survival were lymph node status and adjuvant chemotherapy. Survival rates of the patients, who received adjuvant anthracycline containing chemotherapy were higher, than those in non-anthracycline containing treatment group, but the difference was not statistically significant.
Patients who had lymph node status N2–3 and those who did not receive adjuvant chemotherapy showed worse prognosis and survival than other patients. The impact of chemotherapy type (anthracycline containing or non-anthracycline containing) on patients survival was not statistically significant. |
| doi_str_mv | 10.2478/v10039-011-0047-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_914299199</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1896112614601504</els_id><sourcerecordid>914299199</sourcerecordid><originalsourceid>FETCH-LOGICAL-c380t-398dd955999098b9d5879326d9648e20717a9033707acee0c0f70f29e9399c133</originalsourceid><addsrcrecordid>eNp9kE1PwzAMhiMEYmPwA7igShw4FZyka2M4oYkvaRIXOEdZ6kKmrh1JW2n_nsAGBw6cbFmPX9kPY6ccLkVWqKuBA0hMgfMUICvSfI-NuUKVZgBi_7vPU85FPmJHISwBcpEDHLKREHGaCRyzhxfv1jUlDb2Zzg2ULDyZ0CXWNJb8dWLKZT-YJg7eadV27-TNepNQVZHtkrZJQu8HN5j6mB1Upg50sqsT9np_9zJ7TOfPD0-z23lqpYIulajKEqdTRARUCyynqkAp8hLzTJGAghcGQcoCCmOJwEJVQCWQUCJaLuWEXWxz17796Cl0euWCpbo2DbV90MjjW8gRI3n-h1y2vW_icZrL7_-lyiLFt5T1bQieKr32bmX8RnPQX5L1VrKOkvWXZJ3HnbNdcr9YUfm78WM1AjdbgKKJwZHXwTqKQkvnozddtu6f-E-G8Iif</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1321124384</pqid></control><display><type>article</type><title>Triple negative breast cancer: adjuvant chemotherapy effect on survival</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Steponaviciene, L ; Lachej-Mikeroviene, N ; Smailyte, G ; Aleknavicius, E ; Meskauskas, R ; Didziapetriene, J</creator><creatorcontrib>Steponaviciene, L ; Lachej-Mikeroviene, N ; Smailyte, G ; Aleknavicius, E ; Meskauskas, R ; Didziapetriene, J</creatorcontrib><description>The purpose of this study was to evaluate the overall survival of patients with triple negative breast cancer and the impact of different adjuvant chemotherapy regimens on survival.
The study group consisted of 99 breast cancer patients with immunohistochemically confirmed triple negative breast cancer. The impact of various factors as well as the impact of different chemotherapy regimens on survival was evaluated.
The overall survival of breast cancer patients was 97.0% (95% CI 90.9–99.0), 84.9% (95% CI 76.1–90.6) and 66.5% (95% CI 55.5–75.3) 10, 30 and 60 months after diagnosis, respectively. Univariate analysis demonstrated that the following were significant risk factors for breast cancer patients survival: patient's age, stage of disease, tumour size, lymph node status, type of surgery and chemotherapy. Better survival was related to younger patients’ age, smaller tumour size, lower stage of disease, no lymph nodes involvement. Survival rates were higher among patients who received adjuvant chemotherapy and underwent quadrantectomy. In the multivariate statistical analysis the significant independent prognostic variables influencing survival were lymph node status and adjuvant chemotherapy. Survival rates of the patients, who received adjuvant anthracycline containing chemotherapy were higher, than those in non-anthracycline containing treatment group, but the difference was not statistically significant.
Patients who had lymph node status N2–3 and those who did not receive adjuvant chemotherapy showed worse prognosis and survival than other patients. The impact of chemotherapy type (anthracycline containing or non-anthracycline containing) on patients survival was not statistically significant.</description><identifier>ISSN: 1896-1126</identifier><identifier>EISSN: 1898-4002</identifier><identifier>DOI: 10.2478/v10039-011-0047-6</identifier><identifier>PMID: 22112429</identifier><language>eng</language><publisher>Netherlands: Elsevier Urban & Partner Sp. z o.o</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents - pharmacology ; Breast cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - metabolism ; Breast Neoplasms - mortality ; Chemotherapy, Adjuvant - methods ; Female ; Humans ; Immunohistochemistry - methods ; Middle Aged ; Multivariate Analysis ; Prognosis ; Receptor, ErbB-2 - biosynthesis ; Receptors, Estrogen - biosynthesis ; Receptors, Progesterone - biosynthesis ; Risk Factors ; Time Factors ; Treatment Outcome ; triple negative breast cancer</subject><ispartof>Advances in medical sciences, 2011-12, Vol.56 (2), p.285-290</ispartof><rights>2011 Medical University of Bialystok</rights><rights>Copyright Versita 2011</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c380t-398dd955999098b9d5879326d9648e20717a9033707acee0c0f70f29e9399c133</citedby><cites>FETCH-LOGICAL-c380t-398dd955999098b9d5879326d9648e20717a9033707acee0c0f70f29e9399c133</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22112429$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Steponaviciene, L</creatorcontrib><creatorcontrib>Lachej-Mikeroviene, N</creatorcontrib><creatorcontrib>Smailyte, G</creatorcontrib><creatorcontrib>Aleknavicius, E</creatorcontrib><creatorcontrib>Meskauskas, R</creatorcontrib><creatorcontrib>Didziapetriene, J</creatorcontrib><title>Triple negative breast cancer: adjuvant chemotherapy effect on survival</title><title>Advances in medical sciences</title><addtitle>Adv Med Sci</addtitle><description>The purpose of this study was to evaluate the overall survival of patients with triple negative breast cancer and the impact of different adjuvant chemotherapy regimens on survival.
The study group consisted of 99 breast cancer patients with immunohistochemically confirmed triple negative breast cancer. The impact of various factors as well as the impact of different chemotherapy regimens on survival was evaluated.
The overall survival of breast cancer patients was 97.0% (95% CI 90.9–99.0), 84.9% (95% CI 76.1–90.6) and 66.5% (95% CI 55.5–75.3) 10, 30 and 60 months after diagnosis, respectively. Univariate analysis demonstrated that the following were significant risk factors for breast cancer patients survival: patient's age, stage of disease, tumour size, lymph node status, type of surgery and chemotherapy. Better survival was related to younger patients’ age, smaller tumour size, lower stage of disease, no lymph nodes involvement. Survival rates were higher among patients who received adjuvant chemotherapy and underwent quadrantectomy. In the multivariate statistical analysis the significant independent prognostic variables influencing survival were lymph node status and adjuvant chemotherapy. Survival rates of the patients, who received adjuvant anthracycline containing chemotherapy were higher, than those in non-anthracycline containing treatment group, but the difference was not statistically significant.
Patients who had lymph node status N2–3 and those who did not receive adjuvant chemotherapy showed worse prognosis and survival than other patients. The impact of chemotherapy type (anthracycline containing or non-anthracycline containing) on patients survival was not statistically significant.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - mortality</subject><subject>Chemotherapy, Adjuvant - methods</subject><subject>Female</subject><subject>Humans</subject><subject>Immunohistochemistry - methods</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Prognosis</subject><subject>Receptor, ErbB-2 - biosynthesis</subject><subject>Receptors, Estrogen - biosynthesis</subject><subject>Receptors, Progesterone - biosynthesis</subject><subject>Risk Factors</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>triple negative breast cancer</subject><issn>1896-1126</issn><issn>1898-4002</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kE1PwzAMhiMEYmPwA7igShw4FZyka2M4oYkvaRIXOEdZ6kKmrh1JW2n_nsAGBw6cbFmPX9kPY6ccLkVWqKuBA0hMgfMUICvSfI-NuUKVZgBi_7vPU85FPmJHISwBcpEDHLKREHGaCRyzhxfv1jUlDb2Zzg2ULDyZ0CXWNJb8dWLKZT-YJg7eadV27-TNepNQVZHtkrZJQu8HN5j6mB1Upg50sqsT9np_9zJ7TOfPD0-z23lqpYIulajKEqdTRARUCyynqkAp8hLzTJGAghcGQcoCCmOJwEJVQCWQUCJaLuWEXWxz17796Cl0euWCpbo2DbV90MjjW8gRI3n-h1y2vW_icZrL7_-lyiLFt5T1bQieKr32bmX8RnPQX5L1VrKOkvWXZJ3HnbNdcr9YUfm78WM1AjdbgKKJwZHXwTqKQkvnozddtu6f-E-G8Iif</recordid><startdate>20111201</startdate><enddate>20111201</enddate><creator>Steponaviciene, L</creator><creator>Lachej-Mikeroviene, N</creator><creator>Smailyte, G</creator><creator>Aleknavicius, E</creator><creator>Meskauskas, R</creator><creator>Didziapetriene, J</creator><general>Elsevier Urban & Partner Sp. z o.o</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BYOGL</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20111201</creationdate><title>Triple negative breast cancer: adjuvant chemotherapy effect on survival</title><author>Steponaviciene, L ; Lachej-Mikeroviene, N ; Smailyte, G ; Aleknavicius, E ; Meskauskas, R ; Didziapetriene, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c380t-398dd955999098b9d5879326d9648e20717a9033707acee0c0f70f29e9399c133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - mortality</topic><topic>Chemotherapy, Adjuvant - methods</topic><topic>Female</topic><topic>Humans</topic><topic>Immunohistochemistry - methods</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Prognosis</topic><topic>Receptor, ErbB-2 - biosynthesis</topic><topic>Receptors, Estrogen - biosynthesis</topic><topic>Receptors, Progesterone - biosynthesis</topic><topic>Risk Factors</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>triple negative breast cancer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Steponaviciene, L</creatorcontrib><creatorcontrib>Lachej-Mikeroviene, N</creatorcontrib><creatorcontrib>Smailyte, G</creatorcontrib><creatorcontrib>Aleknavicius, E</creatorcontrib><creatorcontrib>Meskauskas, R</creatorcontrib><creatorcontrib>Didziapetriene, J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>East Europe, Central Europe Database</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Advances in medical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Steponaviciene, L</au><au>Lachej-Mikeroviene, N</au><au>Smailyte, G</au><au>Aleknavicius, E</au><au>Meskauskas, R</au><au>Didziapetriene, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Triple negative breast cancer: adjuvant chemotherapy effect on survival</atitle><jtitle>Advances in medical sciences</jtitle><addtitle>Adv Med Sci</addtitle><date>2011-12-01</date><risdate>2011</risdate><volume>56</volume><issue>2</issue><spage>285</spage><epage>290</epage><pages>285-290</pages><issn>1896-1126</issn><eissn>1898-4002</eissn><abstract>The purpose of this study was to evaluate the overall survival of patients with triple negative breast cancer and the impact of different adjuvant chemotherapy regimens on survival.
The study group consisted of 99 breast cancer patients with immunohistochemically confirmed triple negative breast cancer. The impact of various factors as well as the impact of different chemotherapy regimens on survival was evaluated.
The overall survival of breast cancer patients was 97.0% (95% CI 90.9–99.0), 84.9% (95% CI 76.1–90.6) and 66.5% (95% CI 55.5–75.3) 10, 30 and 60 months after diagnosis, respectively. Univariate analysis demonstrated that the following were significant risk factors for breast cancer patients survival: patient's age, stage of disease, tumour size, lymph node status, type of surgery and chemotherapy. Better survival was related to younger patients’ age, smaller tumour size, lower stage of disease, no lymph nodes involvement. Survival rates were higher among patients who received adjuvant chemotherapy and underwent quadrantectomy. In the multivariate statistical analysis the significant independent prognostic variables influencing survival were lymph node status and adjuvant chemotherapy. Survival rates of the patients, who received adjuvant anthracycline containing chemotherapy were higher, than those in non-anthracycline containing treatment group, but the difference was not statistically significant.
Patients who had lymph node status N2–3 and those who did not receive adjuvant chemotherapy showed worse prognosis and survival than other patients. The impact of chemotherapy type (anthracycline containing or non-anthracycline containing) on patients survival was not statistically significant.</abstract><cop>Netherlands</cop><pub>Elsevier Urban & Partner Sp. z o.o</pub><pmid>22112429</pmid><doi>10.2478/v10039-011-0047-6</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1896-1126 |
| ispartof | Advances in medical sciences, 2011-12, Vol.56 (2), p.285-290 |
| issn | 1896-1126 1898-4002 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_914299199 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adult Aged Aged, 80 and over Antineoplastic Agents - pharmacology Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Breast Neoplasms - mortality Chemotherapy, Adjuvant - methods Female Humans Immunohistochemistry - methods Middle Aged Multivariate Analysis Prognosis Receptor, ErbB-2 - biosynthesis Receptors, Estrogen - biosynthesis Receptors, Progesterone - biosynthesis Risk Factors Time Factors Treatment Outcome triple negative breast cancer |
| title | Triple negative breast cancer: adjuvant chemotherapy effect on survival |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T21%3A02%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Triple%20negative%20breast%20cancer:%20adjuvant%20chemotherapy%20effect%20on%20survival&rft.jtitle=Advances%20in%20medical%20sciences&rft.au=Steponaviciene,%20L&rft.date=2011-12-01&rft.volume=56&rft.issue=2&rft.spage=285&rft.epage=290&rft.pages=285-290&rft.issn=1896-1126&rft.eissn=1898-4002&rft_id=info:doi/10.2478/v10039-011-0047-6&rft_dat=%3Cproquest_cross%3E914299199%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1321124384&rft_id=info:pmid/22112429&rft_els_id=S1896112614601504&rfr_iscdi=true |